GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Legend Biotech Corp (NAS:LEGN) » Definitions » Institutional Ownership

Legend Biotech (Legend Biotech) Institutional Ownership : 60.06% (As of May. 24, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Legend Biotech Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Legend Biotech's institutional ownership is 60.06%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Legend Biotech's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Legend Biotech's Float Percentage Of Total Shares Outstanding is 52.05%.


Legend Biotech Institutional Ownership Historical Data

The historical data trend for Legend Biotech's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Legend Biotech Institutional Ownership Chart

Legend Biotech Historical Data

The historical data trend for Legend Biotech can be seen below:

2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30
Institutional Ownership 62.32 61.59 61.02 60.72 60.53 59.68 60.40 60.86 60.05 60.06

Legend Biotech Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Legend Biotech (Legend Biotech) Business Description

Traded in Other Exchanges
Address
2101 Cottontail Lane, Somerset, NJ, USA, 08873
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy is for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America.